Format

Send to

Choose Destination
Bioorg Med Chem Lett. 1998 Apr 7;8(7):823-8.

The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.

Author information

1
Department of Chemical & Physical Sciences, DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE 19880-0500, USA.

Abstract

Two series of cyclic ureas modified at the P1/P1' residue were prepared and evaluated for HIV protease inhibition and whole cell antiviral activity. Compounds 8b, 10 (3- and 4-pyridylmethyl analogs) and 6b (4-methoxy analog) showed significant improvement in antiviral activity relative to lead compounds DMP323 and DMP 450.

PMID:
9871548
DOI:
10.1016/s0960-894x(98)00119-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center